CoChat

TGF-β1 Pathway as a New Target for Neuroprotection in Alzheimer's Disease: Neuroprotective Role of TGF-β1 in AD

Open access
Caraci, Filippo, Battaglia, Giuseppe, Bruno, Valeria, Bosco, Paolo, Carbonaro, Viviana, Giuffrida, Maria Laura, Drago, Filippo, Sortino, Maria Angela, Nicoletti, Ferdinando, Copani, Agata · 2011 · CNS Neuroscience & Therapeutics
Cited by 135

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that affects more than 37 million people worldwide. Current drugs for AD are only symptomatic, but do not interfere with the underlying pathogenic mechanisms of the disease. AD is characterized by the presence of ß-amyloid (Aβ) plaques, neurofibrillary tangles, and neuronal loss. The identification of the molecular determinants underlying AD pathogenesis is a fundamental step to design new disease-modifying drugs. Recently, a specific impairment of transforming-growth-factor-β1 (TGF-β1) signaling pathway has been demonstrated in AD brain. The deficiency of TGF-β1 signaling has been shown to increase both Aβ accumulation and Aβ-induced neurodegeneration in AD models. The loss of function of TGF-ß1 pathway seems also to contribute to tau pathology and neurofibrillary tangle formation. Growing evidence suggests a neuroprotective role for TGF-β1 against Aβ toxicity both in vitro and in vivo models of AD. Different drugs, such as lithium or group II mGlu receptor agonists are able to increase TGF-β1 levels in the central nervous system (CNS), and might be considered as new neuroprotective tools against Aβ-induced neurodegeneration. In the present review, we examine the evidence for a neuroprotective role of TGF-β1 in AD, and discuss the TGF-β1 signaling pathway as a new pharmacological target for the treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1755-5949.2009.00115.x

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 107

  1. Ballard, 2008, Neuropsychiatric symptoms in dementia: Importance and treatment considerations, Int Rev Psychiatry, 20, 396, 10.1080/09540260802099968 · DOI · Paper page
  2. Mount, 2006, Alzheimer's disease: Progress or profit?, Nature Med, 12, 780, 10.1038/nm0706-780 · DOI · Paper page
  3. Klafki, 2006, Therapeutic approaches to Alzheimer's disease, Brain, 129, 2840, 10.1093/brain/awl280 · DOI · Paper page
  4. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  5. Demuro, 2005, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers, J Biol Chem, 280, 17294, 10.1074/jbc.M500997200 · DOI · Paper page
  6. Mattson, 1992, beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity, J Neurosci, 12, 376, 10.1523/JNEUROSCI.12-02-00376.1992 · DOI · Paper page
  7. Giovanni, 1999, Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F-DP, in β-amyloid-induced neuronal death, J Biol Chem, 274, 19011, 10.1074/jbc.274.27.19011 · DOI · Paper page
  8. Copani, 1999, Mitotic signaling by beta-amyloid causes neuronal death, FASEB J, 13, 2225, 10.1096/fasebj.13.15.2225 · DOI · Paper page
  9. Copani, 2002, Erratic expression of DNA polymerases by beta-amyloid causes neuronal death, FASEB J, 16, 2006, 10.1096/fj.02-0422fje · DOI · Paper page
  10. Herrup, 2004, Divide and die: Cell cycle events as triggers of nerve cell death, J Neurosci, 24, 9232, 10.1523/JNEUROSCI.3347-04.2004 · DOI · Paper page
  11. Copani, 2006, DNA polymerase-ß is early expressed in neurons of Alzheimer's Disease brain and is loaded into DNA replication forks in neurons challenged with ß-amyloid, J Neurosci, 26, 10949, 10.1523/JNEUROSCI.2793-06.2006 · DOI · Paper page
  12. Otth, 2002, AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576, J Alzheimers Dis, 4, 417, 10.3233/JAD-2002-4508 · DOI · Paper page
  13. Takashima, 1998, Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons, Neurosci Res, 31, 317, 10.1016/S0168-0102(98)00061-3 · DOI · Paper page
  14. Lucas, 2001, Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice, EMBO J, 20, 27, 10.1093/emboj/20.1.27 · DOI · Paper page
  15. Hock, 2001, Transgenic mouse models of Alzheimer's disease, Trends Genet, 17, S7, 10.1016/S0168-9525(01)02449-0 · DOI
  16. Malin, 2001, Hippocampal injections of amyloid beta-peptide 1-40 impair subsequent one-trial/day reward learning, Neurobiol Learn Mem, 76, 125, 10.1006/nlme.2000.3991 · DOI
  17. Miguel-Hidalgo, 1998, Beta-amyloid(1-40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield, Acta Neuropathol (Berl), 95, 455, 10.1007/s004010050825 · DOI
  18. Morimoto, 1998, Co-injection of beta-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons, Neuroscience, 84, 479, 10.1016/S0306-4522(97)00507-1 · DOI
  19. Connor, 1998, The role of neuronal growth factors in neurodegenerative disorders of the human brain, Brain Res Brain Res Rev, 27, 1, 10.1016/S0165-0173(98)00004-6 · DOI · Paper page
  20. Castren, 2006, Neurotrophins and dementia-keeping in touch, Neuron, 51, 1, 10.1016/j.neuron.2006.06.019 · DOI
  21. Ten Dijke, 2004, New insights into TGF-beta-Smad signalling, Trends Biochem Sci, 29, 265, 10.1016/j.tibs.2004.03.008 · DOI · Paper page
  22. Taipale, 1998, Extracellular matrixassociated transforming growth factor-beta: Role in cancer cell growth and invasion, Adv Cancer Res, 75, 87, 10.1016/S0065-230X(08)60740-X · DOI · Paper page
  23. Li, 2006, Transforming growth factor-β regulation of immune responses, Annu Rev Immunol, 24, 99, 10.1146/annurev.immunol.24.021605.090737 · DOI · Paper page
  24. Dubois, 1995, Processing of transforming growth factor beta 1 precursor by human furin convertase, J Biol Chem, 270, 10618, 10.1074/jbc.270.18.10618 · DOI · Paper page
  25. Lawrence, 1984, Normal embryo fibroblasts release transforming growth factors in a latent form, J Cell Physiol, 121, 184, 10.1002/jcp.1041210123 · DOI · Paper page
  26. Annes, 2003, Making sense of latent TGFbeta activation, J Cell Sci, 116, 217, 10.1242/jcs.00229 · DOI · Paper page
  27. Shi, 2003, Mechanisms of TGF-beta signaling from cell membrane to the nucleus, Cell, 113, 685, 10.1016/S0092-8674(03)00432-X · DOI · Paper page
  28. Derynck, 2003, Smad-dependent and Smad-independent pathways in TGF-beta family signalling, Nature, 425, 577, 10.1038/nature02006 · DOI · Paper page
  29. Caraci, 2008, TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts, Pharmacol Res, 57, 274, 10.1016/j.phrs.2008.02.001 · DOI · Paper page
  30. König, 2005, TGF-{beta}1 activates two distinct type I receptors in neurons: Implications for neuronal NF-{kappa}B signaling, J Cell Biol, 168, 1077, 10.1083/jcb.200407027 · DOI · Paper page
  31. Vivien, 2006, Transforming growth factor-β signalling in brain disorder, Cytokine Growth Factor Rev, 17, 121, 10.1016/j.cytogfr.2005.09.011 · DOI
  32. Finch, 1993, TGF-β1 is an organizer of response to neurodegeneration, J Cell Biochem, 53, 314, 10.1002/jcb.240530408 · DOI · Paper page
  33. Salvioli, 2009, Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53, Cancer Immunol Immunother, 58, 1909, 10.1007/s00262-008-0639-6 · DOI
  34. Frippiat, 2001, Subcytotoxic H2O2 stress triggers a release of transforming growth factor-beta 1, which induces biomarkers of cellular senescence of human diploid fibroblasts, J Biol Chem, 276, 2531, 10.1074/jbc.M006809200 · DOI · Paper page
  35. Carrieri, 2004, The G/C915 polymorphism of transforming growth factor beta1 is associated with human longevity: A study in Italian centenarians, Aging Cell, 3, 443, 10.1111/j.1474-9728.2004.00129.x · DOI · Paper page
  36. Forsey, 2003, Plasma cytokine profiles in elderly humans, Mech Ageing Dev, 124, 487, 10.1016/S0047-6374(03)00025-3 · DOI · Paper page
  37. Chao, 1994, Serum cytokine levels in patients with Alzheimer's disease, Clin Diagn Lab Immunol, 1, 433, 10.1128/CDLI.1.4.433-436.1994 · DOI · Paper page
  38. Mocali, 2004, Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease, Exp Gerontol, 39, 1555, 10.1016/j.exger.2004.07.007 · DOI
  39. Arosio, 2007, +10 T/C polymorphisms in the gene of transforming growth factor-beta1 are associated with neurodegeneration and its clinical evolution, Mech Ageing Dev, 128, 553, 10.1016/j.mad.2007.07.006 · DOI
  40. Lee, 2006, Ectopic expression of phospho-Smad2 in Alzheimer's disease: Uncoupling of the transforming growth factor-beta pathway?, J Neurosci Res, 84, 1856, 10.1002/jnr.21072 · DOI · Paper page
  41. Ueberham, 2006, Altered subcellular location of phosphorylated Smads in Alzheimer's disease, Eur J Neurosci, 24, 2327, 10.1111/j.1460-9568.2006.05109.x · DOI · Paper page
  42. Chalmers, 2007, Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons, J Neuropathol Exp Neurol, 66, 158, 10.1097/nen.0b013e3180303b93 · DOI · Paper page
  43. Burton, 2002, Transforming growth factor-beta-induced transcription of the Alzheimer beta-amyloid precursor protein gene involves interaction between the CTCFcomplex and Smads, Biochem Biophys Res Commun, 295, 713, 10.1016/S0006-291X(02)00725-8 · DOI
  44. Lesne, 2003, Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice, J Biol Chem, 278, 18408, 10.1074/jbc.M300819200 · DOI · Paper page
  45. Gaertner, 2005, Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities, Neurobiol Dis, 19, 38, 10.1016/j.nbd.2004.11.008 · DOI · Paper page
  46. Harris-White, 1998, Effects of transforming growth factor-beta (isoforms 1-3) on amyloid-beta deposition, inflammation, and cell targeting in organotypic hippocampal slice cultures, J Neurosci, 18, 10366, 10.1523/JNEUROSCI.18-24-10366.1998 · DOI · Paper page
  47. Grammas, 2002, Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain, Am J Pathol, 160, 1583, 10.1016/S0002-9440(10)61105-4 · DOI
  48. Lee, 2005, The amyloid-beta peptide suppresses transforming growth factor-beta1-induced matrix metalloproteinase-2 production via Smad7 expression in human monocytic THP-1 cells, J Biol Chem, 280, 7845, 10.1074/jbc.M409101200 · DOI
  49. Arendt, 2007, Linking cell-cycle dysfunction in Alzheimer's disease to a failure of synaptic plasticity, Biochim Biophys Acta, 1772, 413, 10.1016/j.bbadis.2006.12.005 · DOI
  50. Vincent, 1996, Mitotic mechanisms in Alzheimer's disease?, J Cell Biol, 132, 413, 10.1083/jcb.132.3.413 · DOI · Paper page
  51. Herrup, 2004, Divide and die: Cell cycle events as triggers of nerve cell death, J Neurosci, 24, 9232, 10.1523/JNEUROSCI.3347-04.2004 · DOI · Paper page
  52. Copani, 2007, The nature of the cell cycle in neurons: Focus on a “non-canonical” pathway of DNA replication causally related to death, Biochim Biophys Acta, 1772, 409, 10.1016/j.bbadis.2006.10.016 · DOI
  53. Dhandapani, 2003, Astrocyte protection of neurons: Role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway, J Biol Chem, 278, 43329, 10.1074/jbc.M305835200 · DOI · Paper page
  54. Sortino, 2004, Glia mediates the neuroprotective action of estradiol on beta-amyloid-induced neuronal death, Endocrinology, 145, 5080, 10.1210/en.2004-0973 · DOI · Paper page
  55. Prehn, 1996, Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons, Mol Pharmacol, 49, 319, 10.1016/S0026-895X(25)08714-0 · DOI · Paper page
  56. Ren, 1996, Transforming growth factors-beta protect primary rat hippocampal neuronal cultures from degeneration induced by beta-amyloid peptide, Brain Res, 732, 16, 10.1016/0006-8993(96)00458-1 · DOI
  57. Ren, 1997, Transforming growth factor-beta protects human hNT cells from degeneration induced by beta-amyloid peptide: Involvement of the TGF-beta type II receptor, Brain Res Mol Brain Res, 48, 315, 10.1016/S0169-328X(97)00108-3 · DOI
  58. Kim, 1998, Transforming growth factor-beta inhibits apoptosis induced by beta-amyloid peptide fragment 25-35 in cultured neuronal cells, Brain Res Mol Brain Res, 62, 122, 10.1016/S0169-328X(98)00217-4 · DOI
  59. Inman, 2002, SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7, Mol Pharmacol, 62, 65, 10.1124/mol.62.1.65 · DOI · Paper page
  60. Boche, 2006, TGFbeta1 regulates the inflammatory response during chronic neurodegeneration, Neurobiol Dis, 22, 638, 10.1016/j.nbd.2006.01.004 · DOI · Paper page
  61. Maccioni, 2009, The role of neuroimmunomodulation in Alzheimer's disease, Ann N Y Acad Sci, 1153, 240, 10.1111/j.1749-6632.2008.03972.x · DOI · Paper page
  62. Frautschy, 1992, Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amyloid, Am J Pathol, 140, 1389
  63. Magnus, 2002, Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: Implications for the role of glial cells in the inflamed central nervous system, J Neuropathol Exp Neurol, 61, 760, 10.1093/jnen/61.9.760 · DOI · Paper page
  64. Unsicker, 2000, Co-activation of TGF-β and cytokine signaling pathways are required for neurotropic functions, Cytokine Growth Factor Rev, 11, 97, 10.1016/S1359-6101(99)00033-7 · DOI
  65. Unsicker, 2002, TGF-betas and their roles in the regulation of neuron survival, Adv Exp Med Biol, 513, 353, 10.1007/978-1-4615-0123-7_13 · DOI
  66. Schober, 2007, GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action, Neurobiol Dis, 25, 378, 10.1016/j.nbd.2006.10.005 · DOI · Paper page
  67. Cotman, 2005, The role of neurotrophins in brain aging: A perspective in honor of Regino Perez-Polo, Neurochem Res, 30, 877, 10.1007/s11064-005-6960-y · DOI
  68. Sometani, 2001, Transforming growth factor-beta1 enhances expression of brain-derived neurotrophic factor and its receptor, TrkB, in neurons cultured from rat cerebral cortex, J Neurosci Res, 66, 369, 10.1002/jnr.1229 · DOI · Paper page
  69. Zhu, 2001, TGF-beta1 inhibits caspase-3 activation and neuronal apoptosis in rat hippocampal cultures, Neurochem Int, 38, 227, 10.1016/S0197-0186(00)00084-X · DOI
  70. Zhu, 2002, Transforming growth factor-b1 increases bad phosphorylation and protects neurons against damage, J Neurosci, 22, 3898, 10.1523/JNEUROSCI.22-10-03898.2002 · DOI · Paper page
  71. Zhu, 2004, Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1,2 signaling pathways, Neuroscience, 123, 897, 10.1016/j.neuroscience.2003.10.037 · DOI
  72. Hübscher, 2004, Eukaryotic DNA polymerases, a growing family, Trends Biochem Sci, 25, 143, 10.1016/S0968-0004(99)01523-6 · DOI · Paper page
  73. Yang, 2001, DNA replication precedes neuronal cell death in Alzheimer's disease, J Neurosci, 21, 2661, 10.1523/JNEUROSCI.21-08-02661.2001 · DOI · Paper page
  74. Slee, 2004, To die or not to die: How does p53 decide?, Oncogene, 23, 2809, 10.1038/sj.onc.1207516 · DOI · Paper page
  75. Paradis, 1996, Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons, J Neurosci, 16, 7533, 10.1523/JNEUROSCI.16-23-07533.1996 · DOI · Paper page
  76. Caricasole, 2004, Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain, J Neurosci, 24, 6021, 10.1523/JNEUROSCI.1381-04.2004 · DOI · Paper page
  77. Fuentealba, 2004, Signal transduction during amyloid-beta-peptide neurotoxicity: Role in Alzheimer disease, Brain Res Brain Res Rev, 47, 275, 10.1016/j.brainresrev.2004.07.018 · DOI
  78. Murase, 2002, Depolarization drives beta-catenin into neuronal spines promoting changes in synaptic structure and function, Neuron, 35, 91, 10.1016/S0896-6273(02)00764-X · DOI · Paper page
  79. Yu, 2003, Beta-catenin is critical for dendritic morphogenesis, Nat Neurosci, 6, 1169, 10.1038/nn1132 · DOI · Paper page
  80. Liolitsa, 2002, Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease, J Neurol Neurosurg Psychiatry, 73, 261, 10.1136/jnnp.73.3.261 · DOI · Paper page
  81. Castri, 2007, Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease, Eur J Neurosci, 26, 2469, 10.1111/j.1460-9568.2007.05869.x · DOI
  82. Pollack, 2002, Small molecule Trk receptor agonists and other neurotrophic factor mimetics, Curr Drug Targets CNS Neurol Disord, 1, 59, 10.2174/1568007023339490 · DOI
  83. Skaper, 2008, The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors, CNS Neurol Disord Drug Targets, 7, 46, 10.2174/187152708783885174 · DOI · Paper page
  84. Zhang, 2005, Small molecule tgf-beta mimetics as potential neuroprotective factors, Curr Alzheimer Res, 2, 183, 10.2174/1567205053585756 · DOI
  85. Brinton, 2004, Impact of estrogen therapy on Alzheimer's disease: A fork in the road?, CNS Drugs, 18, 405, 10.2165/00023210-200418070-00001 · DOI
  86. Chen, 2006, Dose and temporal pattern of estrogen exposure determines neuroprotective outcome in hippocampal neurons: Therapeutic implications, Endocrinology, 147, 5303, 10.1210/en.2006-0495 · DOI · Paper page
  87. Redondo, 2007, TGF-beta1: A novel target for cardiovascular pharmacology, Cytokine Growth Factor Rev, 18, 279, 10.1016/j.cytogfr.2007.04.005 · doi:10.1016/j.cytogfr.2007.04.005
  88. Broe, 2000, Anti-inflammatory drugs protect against Alzheimer disease at low doses, Arch Neurol, 57, 1586, 10.1001/archneur.57.11.1586 · DOI · Paper page
  89. Li, 2007, Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease, Neurology, 69, 878, 10.1212/01.wnl.0000277657.95487.1c · DOI · Paper page
  90. Sparks, 2008, Reduced risk of incident AD with elective statin use in a clinical trial cohort, Curr Alzheimer Res, 5, 416, 10.2174/156720508785132316 · DOI · Paper page
  91. Redondo, 2003, Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-beta, Circulation, 107, 626, 10.1161/01.CIR.0000045664.75269.A5 · DOI
  92. Grainger, 1995, The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis, Nat Med, 1, 174, 10.1038/nm0195-74 · DOI · Paper page
  93. Porreca, 2002, Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutarylcoenzyme a reductase inhibition with pravastatin, J Am Coll Cardiol, 39, 1752, 10.1016/S0735-1097(02)01857-0 · doi:10.1016/s0735-1097(02)01857-0
  94. Nakamura, 2006, Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting, Cytokine, 36, 201, 10.1016/j.cyto.2006.11.001 · DOI
  95. Simpson, 2002, Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis, CNS Drugs, 16, 825, 10.2165/00023210-200216120-00004 · DOI
  96. Arnon, 2004, Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications, Proc Natl Acad Sci U S A, 101, 14593, 10.1073/pnas.0404887101 · DOI · Paper page
  97. Aharoni, 2005, The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice, Proc Natl Acad Sci U S A, 102, 19045, 10.1073/pnas.0509438102 · DOI · Paper page
  98. Breivik, 2006, Enhanced susceptibility to periodontitis in an animal model of depression: Reversed by chronic treatment with the anti-depressant tianeptine, J Clin Periodontol, 33, 469, 10.1111/j.1600-051X.2006.00935.x · DOI
  99. Vollmar, 2008, Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model, Int J Neuropsychopharmacol, 11, 111, 10.1017/S1461145707007729 · DOI · Paper page
  100. Modrego, 2004, Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: A prospective cohort study, Arch Neurol, 61, 1290, 10.1001/archneur.61.8.1290 · DOI · Paper page
  101. Wada, 2005, Lithium: Potential therapeutics against acute brain injuries and chronic neurodegenerative diseases, J Pharmacol Sci, 99, 307, 10.1254/jphs.CRJ05009X · DOI · Paper page
  102. Yeh, 2008, Lithium may be useful in the prevention of Alzheimer's disease in individuals at risk of presenile familial Alzheimer's disease, Med Hypotheses, 71, 948, 10.1016/j.mehy.2008.03.049 · DOI
  103. Nunes, 2007, Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder, Br J Psychiatry, 190, 359, 10.1192/bjp.bp.106.029868 · DOI · Paper page
  104. Liang, 2008, Lithium inhibits Smad 3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling, Mol Cell Neurosc, 37, 440, 10.1016/j.mcn.2007.10.017 · DOI
  105. Bruno, 1998, Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta, J Neurosci, 18, 9594, 10.1523/JNEUROSCI.18-23-09594.1998 · DOI · Paper page
  106. D’Onofrio, 2001, Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways, J Neurochem, 78, 435, 10.1046/j.1471-4159.2001.00435.x · DOI
  107. Copani, 1995, Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide, Mol Pharmacol, 47, 890, 10.1016/S0026-895X(25)08600-6 · DOI · Paper page

Cited by

See all 135

Metadata

Authors
Caraci, F., Battaglia, G., Bruno, V., Bosco, P., Carbonaro, V., Giuffrida, M. L., Drago, F., Sortino, M. A., Nicoletti, F., & Copani, A.
Venue
CNS Neuroscience & Therapeutics
Publisher
Wiley
Published
2009-11-19
Volume
17
Issue
4
Pages
237-249
ISSN
1755-5930 (ISSN-L)
OpenAlex
W1582623884
Cited by
135
References
27
FWCI
3.74
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2112 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TGF-β1 Pathway as a New Target for Neuroprotection in Alzheimer's Disease: Neuroprotective Role of TGF-β1 in AD. https://app.cochat.ai/papers/10.1111/j.1755-5949.2009.00115.x
The paper
Caraci, F., Battaglia, G., Bruno, V., Bosco, P., Carbonaro, V., Giuffrida, M. L., Drago, F., Sortino, M. A., Nicoletti, F., & Copani, A. (2011). TGF-β1 Pathway as a New Target for Neuroprotection in Alzheimer's Disease: Neuroprotective Role of TGF-β1 in AD. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2009.00115.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.